Genetically engineered biological agents in therapy for systemic lupus erythematosus
https://doi.org/10.14412/1996-7012-2013-11
Abstract
Systemic lupus erythematosus (SLE) is a prototype for chronic autoimmune disease. Its prevalence is 20 to 70 cases per 100,000 women and varies by race and ethnicity. Despite considerable progress in traditional therapy, many problems associated with the management of these patients need to be immediately solved: thus, 50-80% are found to have activity signs and/or frequent exacerbations and about 30% of the patients have to stop work; Class IV lupus nephritis increases the risk of terminalrenal failure. In the past 20 years great progress has been made in studying the pathogenesis of SLE: biological targets to affect drugs have been sought and fundamentally new therapeutic goals defined. Belimumab is the first genetically biological agent specially designed to treat SLE, which is rightly regarded as one of the most important achievements of rheumatology in the past 50 years.
About the Authors
Elena Aleksandrovna Aseeva
V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
S K Solovyev
V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow
E L Nasonov
V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow
References
1. <div><p>Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526–33. DOI: 10.1056%2FNEJMoa021933.</p><p>James JA, Harley JB, Scofield RH. Epstein-Barr virus and systemic lupus erythematosus. Curr Opin Rheumatol. 2006;18(5):462–7. DOI: 10.1097%2F01.bor.0000240355.37927.94.</p><p>Costenbader KH, Gay S, Alarcón-Riquelme ME et al. Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun Rev. 2012;11(8):604-9. DOI: 10.1016/j.autrev.2011.10.022. Epub 2011 Oct 25.</p><p>Pons-Estel GJ, Alarcón GS, Scofield L et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010; 39(4):257-68. DOI: 10.1016/j.semarthrit.2008.10.007. Epub 2009 Jan 10.</p><p>Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308–18. DOI: 10.1191%2F0961203306lu2305xx.</p><p>Helmick CG, Felson DT, Lawrence RC et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15–25. DOI: 10.1002/art.23177.</p><p>Bernatsky S, Boivin JF, Joseph L et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550–7. DOI: 10.1002%2Fart.21955.</p><p>Nikpour M, Urowitz MB, Ibañez D, Gladman DD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum, 2009;61(9):1152–8. DOI: 10.1002/art.24741.</p><p>Yelin E, Tonner C, Trupin L et al. Longitudinal study of the impact of incident organ anifestations and increased disease activity on work loss among persons with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64(2):169–75. DOI: 10.1002/acr.20669.</p><p>Rose BD, Appel GB. End-stage renal disease due to lupus nephritis. UpToDate, 2012 (http://www.uptodate.com/contents/end-stage-renal-disease-due-to-lupus -nephritis).</p><p>Fessler BJ, Alarcón GS, McGwin G Jr et al. Systemic lupus erythematosus in three ethnic groups. XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52(5):1473–80. DOI: 10.1002%2Fart.21039.</p><p>Slawsky KA, Fernandes AW, Fusfeld L et al. A structured literature review of the direct costs of adult systemic lupus erythematosus in the US. Arthritis Care Res (Hoboken). 2011;63(9):1224–32. DOI: 10.1002/acr.20502.</p><p>Petri M et al. Derivation and Validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum. 2012;64(8):2677–86. DOI: 10.1002/art.34473.</p><p>Jordan B, Lutalo PMK, D’Cruz DP. Novel therapeutic agents in clinical development for systemic lupus erythematosus. BMC Med. 2013;11:120. DOI: 10.1186/1741-7015-11-120.</p><p>Furie RA, Petri MA, Wallace DJ et al. Novel evidencebased systemic lupus erythematosus responder index. Arthritis Rheum. 2009;(61):1143–51.</p><p>Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000;43(8):1801–8. DOI: 10.1002%2F1529-0131%28200008%2943%3A8%3C1801%3A%3AAID-ANR16%3E3.0.CO%3B2-O.</p><p>Sanz I, Lee FE. B-cells as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6(6):326–37. DOI: 10.1038/nrrheum.2010.68.</p><p>Leandro MJ, Cambridge G, Edwards JC et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford). 2005;44(12):1542–5. DOI: 10.1093%2Frheumatology%2Fkei080. Epub 2005 Sep 27.</p><p>Lindholm C, Börjesson-Asp K, Zendjanchi K et al. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol. 2008;35(5):826–33. Epub 2008 Apr 1.</p><p>Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50(8):2580–9. DOI: 10.1002%2Fart.20430 .</p><p>Turner-Stokes T, Lu TY, Ehrenstein MR et al. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford). 2011;50(8):1401–8. DOI: 10.1093/rheumatology/ker018. Epub 2011 Mar 12.</p><p>Terrier B, Amoura Z, Ravaud P et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010;62(8):2458–66. DOI: 10.1002/art.27541.</p><p>Furie R, Looney RJ, Rovin B et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum. 2009;60(Suppl 1):S429.</p><p>Lightstone L. The landscape after LUNAR: rituximab’s crater-filled path. Arthritis Rheum. 2012;64(4):962–5. DOI: 10.1002/art.34362. Epub 2012 Jan 9.</p><p>Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus:the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222–33. DOI: 10.1002/art.27233.</p><p>Pepper R, Griffith M, Kirwan C et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant. 2009;24(12):3717–23. DOI: 10.1093/ndt/gfp336. Epub 2009 Jul 17.</p><p>Traczewski P, Rudnicka L. Treatment of systemic lupus erythematosus with epratuzumab. Br J Clin Pharmacol. 2011;71(2):175–82. DOI: 10.1111/j.1365-2125.2010.03767.x.</p><p>Jacobi AM, Goldenberg DM, Hiepe F et al. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis. 2008;67(4):450–7. DOI: /10.1136%2Fard.2007.075762. Epub 2007 Aug 2.</p><p>FDA approves Benlysta to treat lupus. [Last accessed on 2011 Mar 28]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm246489.htm</p><p>European Medicines Agency. Benlysta: belimumab. 9cited August 8, 2011). Available from: www.ema.ruropa.eu/ema/index/jsp?curl=pages/medicines/human/medicines.002015/human_med_001466.jsp&mid=WC0bac058001d124</p><p>Lied GA, Berstad A. Functional and clinical aspects of the B cell-activation factor (BAFF): a narrative review. Scand J Immunol. 2011;73(1):1–7. DOI: 10.1111/j.1365-3083.2010.02470.x.</p><p>Moore PA, Belvedere O, Orr A. et al. BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285(5425):260–3. DOI: 10.1126%2Fscience.285.5425.260.</p><p>Schneider P, MacKay F, Steiner V et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189(11):1747–56. DOI: 10.1084%2Fjem.189.11.1747.</p><p>Treml JF, Hao Y, Stadanlick JE et al. The BLyS family: Toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys. 2009;53(1):1–16. DOI: 10.1007/s12013-008-9036-1. Epub 2008 Nov 26.</p><p>Gross JA, Johnston J, Murdi S et al. TACI and BCMA are receptors for TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404(6781):995–9.</p><p>Stohl W, Metyas S, Tan SM et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthritis Rheum. 2003;48(12):3475–86. DOI: 10.1002%2Fart.11354.</p><p>Petri M, Stohl W, Chatham W et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58(2):2453–9.DOI: 10.1002/art.23678.</p><p>Sanz I. Targeting B-cell in SLE: good news at last. Nat Rev Rheum. 2011; 7(5):255-6. DOI: 10.1038/nrrheum.2011.48.</p><p>Halpern WG, Lappin P, Zanardi T et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: Pharmacokinetic, pharmacodynamic, and toxicologic effects.Toxicol Sci. 2006;91(2):586–99. DOI: 10.1093%2Ftoxsci%2Fkfj148. Epub 2006 Mar 3.</p><p>Baker KP, Edwards BM, Main SH et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48(11):3253–65. DOI: /10.1002%2Fart.11299.</p><p>Label approved on 03/10/2011 (PDF) for BENLYSTA, BLA no.125370 [Last accessed 2011 Mar 28]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/12537</p><p>Navarra SV, Guzman RM, Gallacher AE et al. BLISS-52 Study Group.Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–31. DOI: 10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4.</p><p>Furie R, Petri M, Zamani E et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–30. DOI: 10.1002/art.30613.</p><p>Furie RA, Petri MA, Wallace DJ et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61(9):1143–51. DOI: 10.1002/art.24698.</p><p>Furie R, Petri M, Zamani E et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–30. DOI: 10.1002/art.30613.</p><p>Manzi S, Sanchez-Guerrero J, Merrill JT et al. Effects of belimumab,a B lymphocyte stimulator-specigic inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012; 71(11):1833-8. DOI: 10.1136/annrheumdis-2011-200831. Epub 2012 May 1.</p><p>Van Vollenhoven RF, Petri MA, Cervera R et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012; 71(8):1343-9. DOI: 10.1136/annrheumdis-2011-200937. Epub 2012 Feb 15.</p><p>Jacobi AM, Odendahl M, Reiter K et al. Correlation between circulating CD29high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2003;48(5):1332–42. DOI: 10.1002%2Fart.10949</p><p>Petri M, Singh S, Tesfasyone H et al. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study. J Rheumatol. 2009;36(11):2476–80. DOI: 10.3899/jrheum.090019. Epub 2009 Oct 15.</p><p>Tseng CE, Buyon JP, Kim M et al. The effect of moderate dose corticosteroids in preventing of severe flares in patients with serologically active, but clinically stable systemic lupus erythematosus: finding of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(11):3623–32. DOI: 10.1002%2Fart.22198.</p><p>Merril JT, Ginzler EM, Wallace DJ et al. Long-term safety profile of belimumab plus standart therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 2012; 64(10):3364-73. DOI: 10.1002/art.34564.</p><p>Molta С et al. Outcomes Associated with Belimumab in Patients with Systemic Lupus Erythematous (SLE) in Clinical Practice Settings: Results from OBSErve Study in the United States (U.S.). Lupus. 22, Abstr Suppl; 036, 2013.</p><p>Ramos-Casals M et al. Recomendaciones sobre el uso de belimumab en el lupus eritematoso sistémico. Guía de Práctica Clínica GEAS-SEMI. Rev Clin Esp. 2012; 213(1):66–7. DOI: 10.1016/j.rce.2012.10.004.</p></div><br />
Review
For citations:
Aseeva EA, Solovyev SK, Nasonov EL. Genetically engineered biological agents in therapy for systemic lupus erythematosus. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2013;7(3):33-40. (In Russ.) https://doi.org/10.14412/1996-7012-2013-11
Views:
4713
Email this article 